Get Your Personalized Supplement StackSupplement Stack Quiz

Cordyceps Sinensis Isolate

Also known as: Cordyceps sinensis, Ophiocordyceps sinensis, Caterpillar fungus, Dong Chong Xia Cao, Bailing capsule

Overview

Cordyceps sinensis, also known as Ophiocordyceps sinensis, is a parasitic fungus traditionally used in Traditional Chinese Medicine (TCM). It is harvested from caterpillars in the Tibetan Plateau. Isolates refer to purified extracts or preparations derived from the fungus. It is primarily used as an adjunctive treatment in chronic kidney disease (CKD), dialysis patients, and for improving lung function and exercise endurance. Key characteristics include bioactive polysaccharides, nucleosides (e.g., cordycepin), and amino acids with purported immunomodulatory, anti-inflammatory, and antioxidant properties. Research maturity is moderate, with several randomized controlled trials (RCTs) and meta-analyses, though many studies have methodological limitations. Evidence is mixed but generally supportive of benefits in CKD and dialysis contexts, however, many studies lack rigorous blinding and allocation concealment, limiting confidence.

Benefits

Cordyceps sinensis isolate has shown potential benefits in several areas. Meta-analyses indicate improvements in renal function markers and inflammatory factors in CKD patients. Studies also suggest enhanced lung function, exercise endurance, and quality of life in stable COPD patients. Furthermore, it may reduce cardiovascular events and improve the micro-inflammatory state in dialysis patients, with statistically significant improvements in outcomes like mortality and infection rates. These benefits are attributed to its anti-inflammatory and antioxidant effects, as well as potential immunomodulatory properties. Patients with CKD and those undergoing hemodialysis (HD) or peritoneal dialysis (PD) show the most consistent benefits. Benefits are typically observed over weeks to months of treatment.

How it works

Cordyceps sinensis isolate works through several biological pathways. It modulates inflammatory cytokines and oxidative stress pathways, enhancing renal cellular repair mechanisms and reducing fibrosis in kidney tissue. It also improves microcirculation and cardiovascular function. The isolate interacts with the immune system by reducing chronic inflammation and supports the renal system via anti-inflammatory and antioxidant effects. In the respiratory system, it enhances lung function and endurance. Molecular targets include cytokines such as TNF-α, IL-6, and TGF-β, as well as antioxidant enzymes and signaling pathways related to oxidative stress. Polysaccharides and nucleosides are bioavailable, but this varies depending on the preparation.

Side effects

Cordyceps sinensis isolate is generally well-tolerated with a good safety profile in clinical studies. Common side effects are minimal, with mild gastrointestinal discomfort occasionally reported. Uncommon side effects include rare allergic reactions or mild skin rashes, occurring in 1-5% of users. No serious adverse events have been consistently reported. Drug interactions are limited, but caution is advised when combined with immunosuppressants or anticoagulants due to potential additive effects. There are no formal contraindications established, but caution is recommended in immunocompromised patients. Safety in pregnant or breastfeeding women has not been well studied. Overall, it is considered safe, but monitoring for potential interactions and individual reactions is advisable.

Dosage

The minimum effective dose of Cordyceps sinensis isolate varies by preparation, but clinical trials often use standardized extracts equivalent to 1–3 grams of raw Cordyceps per day. Bailing capsule studies typically use doses standardized to polysaccharide content, with exact dosing varying by formulation. The maximum safe dose is not well defined, but doses used in trials have not reported dose-limiting toxicity. Daily administration over several weeks to months is required for clinical effects. Capsules or extracts standardized for polysaccharides and nucleosides are preferred for consistency. Bioavailability may be enhanced with food, and the extraction method influences active compound concentration. There are no specifically identified required cofactors.

FAQs

Is Cordyceps sinensis isolate safe for long-term use?

Current evidence suggests good safety for several months of use, but long-term safety data are limited. Monitor for any adverse effects and consult with a healthcare provider.

How soon can benefits be expected?

Clinical improvements are typically observed after weeks to a few months of consistent use. Individual responses may vary, and patience is recommended.

Can it replace conventional treatments?

No, it is used as an adjunctive therapy, especially in CKD and dialysis patients. It should not replace prescribed medications without consulting a healthcare professional.

Are all Cordyceps products equivalent?

No, chemical composition varies by preparation, affecting efficacy and safety. Choose products standardized for active compounds like polysaccharides and nucleosides.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/39839641/ – This meta-analysis of RCTs assessed the efficacy of Cordyceps sinensis as an adjunctive treatment in chronic diseases. It found statistically significant improvements in clinical outcomes with low to moderate heterogeneity. However, the study acknowledges limitations including variability in study quality and small sample sizes in some trials.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1360997/full – This systematic review and meta-analysis examined the effects and safety of Ophiocordyceps sinensis preparations in dialysis patients. The study included multiple RCTs with adequate sample sizes and demonstrated reduced cardiovascular events, improved inflammatory markers, and better quality of life with statistical significance. Rigorous meta-analytic methods, including heterogeneity assessment and random-effects models, were employed.
https://onlinelibrary.wiley.com/doi/10.1155/2019/4903671 – This meta-analysis analyzed RCTs on the effectiveness and safety of oral Cordyceps sinensis on stable COPD, with n≥30 per group on lung function and exercise capacity. It reported moderate effect sizes favoring Cordyceps preparations with improved FEV1 and 6-minute walk distance. The study noted limitations including potential publication bias and lack of blinding in some studies.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1342831/full – This meta-analysis showed significant improvements in renal function and inflammatory factors in CKD patients using Bailing capsules (Cordyceps sinensis). Network pharmacology identified key active compounds and pathways, supporting biological plausibility. The study quality was limited by incomplete reporting of randomization and blinding.
https://journals.lww.com/md-journal/fulltext/2022/11180/effects_and_safety_of_ophiocordyceps_sinensis.114.aspx – This study investigated the effects and safety of Ophiocordyceps sinensis in dialysis patients. The results indicated potential benefits in reducing cardiovascular events and improving inflammatory markers. However, further research is needed to confirm these findings and establish optimal dosage and treatment duration.